Warning: The NCBI web site requires JavaScript to function. more...
Candidate polyanion microbicides inhibit HIV-1 infection and dissemination pathways in human cervical explants.
Fletcher PS, Wallace GS, Mesquita PM, Shattock RJ.
Retrovirology. 2006 Aug 1;3:46.
Related citations
Clinical development of microbicides for the prevention of HIV infection.
D'Cruz OJ, Uckun FM.
Curr Pharm Des. 2004;10(3):315-36. Review.
The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells.
Fletcher P, Kiselyeva Y, Wallace G, Romano J, Griffin G, Margolis L, Shattock R.
J Virol. 2005 Sep;79(17):11179-86.
Inhibitory effect of PRO 2000, a candidate microbicide, on dendritic cell-mediated human immunodeficiency virus transfer.
Teleshova N, Chang T, Profy A, Klotman ME.
Antimicrob Agents Chemother. 2008 May;52(5):1751-8. Epub 2008 Mar 10.
Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
Fletcher P, Harman S, Azijn H, Armanasco N, Manlow P, Perumal D, de Bethune MP, Nuttall J, Romano J, Shattock R.
Antimicrob Agents Chemother. 2009 Feb;53(2):487-95. Epub 2008 Nov 24.
Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models.
Buffa V, Stieh D, Mamhood N, Hu Q, Fletcher P, Shattock RJ.
J Gen Virol. 2009 Jan;90(Pt 1):234-43.
The candidate sulfonated microbicide, PRO 2000, has potential multiple mechanisms of action against HIV-1.
Huskens D, Vermeire K, Profy AT, Schols D.
Antiviral Res. 2009 Oct;84(1):38-47. Epub 2009 Aug 5.
Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides.
Greenhead P, Hayes P, Watts PS, Laing KG, Griffin GE, Shattock RJ.
J Virol. 2000 Jun;74(12):5577-86.
PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes.
Kawamura T, Bruse SE, Abraha A, Sugaya M, Hartley O, Offord RE, Arts EJ, Zimmerman PA, Blauvelt A.
J Virol. 2004 Jul;78(14):7602-9. Erratum in: J Virol. 2004 Oct;78(19):10837. Bruce, Shannon E [corrected to Bruse, Shannon E].
Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides.
Lackman-Smith C, Osterling C, Luckenbaugh K, Mankowski M, Snyder B, Lewis G, Paull J, Profy A, Ptak RG, Buckheit RW Jr, Watson KM, Cummins JE Jr, Sanders-Beer BE.
Antimicrob Agents Chemother. 2008 May;52(5):1768-81. Epub 2008 Mar 3.
Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue.
Hu Q, Frank I, Williams V, Santos JJ, Watts P, Griffin GE, Moore JP, Pope M, Shattock RJ.
J Exp Med. 2004 Apr 19;199(8):1065-75. Epub 2004 Apr 12.
PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial.
Keller MJ, Zerhouni-Layachi B, Cheshenko N, John M, Hogarty K, Kasowitz A, Goldberg CL, Wallenstein S, Profy AT, Klotman ME, Herold BC.
J Infect Dis. 2006 Jan 1;193(1):27-35. Epub 2005 Nov 17.
HIV-1 infection of human penile explant tissue and protection by candidate microbicides.
Fischetti L, Barry SM, Hope TJ, Shattock RJ.
AIDS. 2009 Jan 28;23(3):319-28.
R5- and X4-HIV-1 use differentially the endometrial epithelial cells HEC-1A to ensure their own spread: implication for mechanisms of sexual transmission.
Saïdi H, Magri G, Nasreddine N, Réquena M, Bélec L.
Virology. 2007 Feb 5;358(1):55-68. Epub 2006 Aug 24.
Molecular umbrellas: a novel class of candidate topical microbicides to prevent human immunodeficiency virus and herpes simplex virus infections.
Madan RP, Mesquita PM, Cheshenko N, Jing B, Shende V, Guzman E, Heald T, Keller MJ, Regen SL, Shattock RJ, Herold BC.
J Virol. 2007 Jul;81(14):7636-46. Epub 2007 May 9.
The role of DC-SIGN and DC-SIGNR in HIV and Ebola virus infection: can potential therapeutics block virus transmission and dissemination?
Baribaud F, Doms RW, Pöhlmann S.
Expert Opin Ther Targets. 2002 Aug;6(4):423-31. Review.
Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture.
Cummins JE Jr, Guarner J, Flowers L, Guenthner PC, Bartlett J, Morken T, Grohskopf LA, Paxton L, Dezzutti CS.
Antimicrob Agents Chemother. 2007 May;51(5):1770-9. Epub 2007 Mar 12.
A dual chamber model of female cervical mucosa for the study of HIV transmission and for the evaluation of candidate HIV microbicides.
Van Herrewege Y, Michiels J, Waeytens A, De Boeck G, Salden E, Heyndrickx L, van den Mooter G, de Béthune MP, Andries K, Lewi P, Praet M, Vanham G.
Antiviral Res. 2007 May;74(2):111-24. Epub 2006 Nov 7.
Candidate microbicides block HIV-1 infection of human immature Langerhans cells within epithelial tissue explants.
Kawamura T, Cohen SS, Borris DL, Aquilino EA, Glushakova S, Margolis LB, Orenstein JM, Offord RE, Neurath AR, Blauvelt A.
J Exp Med. 2000 Nov 20;192(10):1491-500.
Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action.
Scordi-Bello IA, Mosoian A, He C, Chen Y, Cheng Y, Jarvis GA, Keller MJ, Hogarty K, Waller DP, Profy AT, Herold BC, Klotman ME.
Antimicrob Agents Chemother. 2005 Sep;49(9):3607-15.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on